Aurobindo Pharma Ltd. - Research Center
524804 AUROPHARMA Group (A) BSE data
Add to watchlist
| Results |
Quarterly
|
| Statement | |
| More |
Quarterly results in brief
(Rs crore)
| Mar' 24 | Dec' 23 | Sep' 23 | Jun' 23 | Mar' 23 | |
|---|---|---|---|---|---|
| Sales | 2,894.03 | 2,692.03 | 2,668.76 | 2,390.82 | 3,547.44 |
| Operating profit | 774.79 | 481.69 | 545.18 | 422.38 | 691.83 |
| Interest | 53.07 | 61.25 | 36.69 | 31.59 | 48.97 |
| Gross profit | 844.69 | 751.57 | 575.57 | 485.67 | 931.03 |
| EPS (Rs) | 9.88 | 10.65 | 7.10 | 5.73 | 11.01 |
Quarterly
results in details
| Mar' 24 | Dec' 23 | Sep' 23 | Jun' 23 | Mar' 23 | |
|---|---|---|---|---|---|
| Other income | 122.97 | 331.13 | 67.08 | 94.88 | 288.17 |
| Stock adjustment | -13.10 | -59.76 | -27.12 | -16.25 | -260.97 |
| Raw material | 1,401.56 | 1,465.93 | 1,518.33 | 1,375.26 | 2,057.46 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 248.91 | 248.08 | 247.51 | 236.06 | 406.77 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 481.87 | 556.09 | 384.86 | 373.37 | 652.35 |
| Provisions made | - | - | - | - | - |
| Depreciation | 64.81 | 64.35 | 65.79 | 59.63 | 115.00 |
| Taxation | 201.21 | 63.44 | 130.13 | 90.09 | 171.23 |
| Net profit / loss | 578.67 | 623.78 | 415.74 | 335.95 | 644.80 |
| Extra ordinary item | - | - | 36.09 | - | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 58.59 | 58.59 | 58.59 | 58.59 | 58.59 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 26.77 | 17.89 | 20.43 | 17.67 | 19.50 |
| GPM (%) | 28.00 | 24.86 | 21.04 | 19.54 | 24.27 |
| NPM (%) | 19.18 | 20.63 | 15.20 | 13.52 | 16.81 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis